Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 03/04/24
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare ConferenceGlobeNewsWire • 02/26/24
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingGlobeNewsWire • 02/23/24
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare ConferenceGlobeNewsWire • 02/07/24
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common StockGlobeNewsWire • 02/06/24
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingGlobeNewsWire • 02/05/24
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 02/02/24
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming MilestonesGlobeNewsWire • 01/05/24
Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023GlobeNewsWire • 12/10/23
Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous UrticariaGlobeNewsWire • 11/30/23
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/23
Jasper Therapeutics to Participate at Upcoming Medical and Investor ConferencesGlobeNewsWire • 11/08/23
Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023GlobeNewsWire • 11/02/23
Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of DirectorsGlobeNewsWire • 11/01/23
Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023GlobeNewsWire • 10/09/23
Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous UrticariaGlobeNewsWire • 10/09/23
Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific SymposiumGlobeNewsWire • 09/21/23
Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare ConferenceGlobeNewsWire • 09/15/23
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/11/23
Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeGlobeNewsWire • 06/22/23